- Home
- LXRX vs ERAS Comparison
LXRX vs ERAS Comparison
Compare LXRX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- ERAS
- Stock Information
- Founded
- LXRX 1995
- ERAS 2018
- Country
- LXRX United States
- ERAS United States
- Employees
- LXRX N/A
- ERAS N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- LXRX Health Care
- ERAS Health Care
- Exchange
- LXRX Nasdaq
- ERAS Nasdaq
- Market Cap
- LXRX 428.8M
- ERAS 484.4M
- IPO Year
- LXRX 2000
- ERAS 2021
- Fundamental
- Price
- LXRX $1.19
- ERAS $1.60
- Analyst Decision
- LXRX Buy
- ERAS Strong Buy
- Analyst Count
- LXRX 5
- ERAS 6
- Target Price
- LXRX $3.23
- ERAS $4.50
- AVG Volume (30 Days)
- LXRX 2.4M
- ERAS 749.3K
- Earning Date
- LXRX 08-06-2025
- ERAS 08-12-2025
- Dividend Yield
- LXRX N/A
- ERAS N/A
- EPS Growth
- LXRX N/A
- ERAS N/A
- EPS
- LXRX N/A
- ERAS N/A
- Revenue
- LXRX $58,432,000.00
- ERAS N/A
- Revenue This Year
- LXRX N/A
- ERAS N/A
- Revenue Next Year
- LXRX N/A
- ERAS N/A
- P/E Ratio
- LXRX N/A
- ERAS N/A
- Revenue Growth
- LXRX 1504.83
- ERAS N/A
- 52 Week Low
- LXRX $0.28
- ERAS $1.01
- 52 Week High
- LXRX $2.18
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- LXRX 56.85
- ERAS 55.28
- Support Level
- LXRX $1.12
- ERAS $1.44
- Resistance Level
- LXRX $1.27
- ERAS $1.68
- Average True Range (ATR)
- LXRX 0.09
- ERAS 0.11
- MACD
- LXRX -0.00
- ERAS 0.00
- Stochastic Oscillator
- LXRX 68.00
- ERAS 67.69
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.